Show simple item record

dc.contributor.authorPalma, Giuseppe
dc.contributor.authorPasqua, Teresa
dc.contributor.authorSilvestri, Giovannino
dc.contributor.authorRocca, Carmine
dc.contributor.authorGualtieri, Paola
dc.contributor.authorBarbieri, Antonio
dc.contributor.authorDe Bartolo, Anna
dc.contributor.authorDe Lorenzo, Antonino
dc.contributor.authorAngelone, Tommaso
dc.contributor.authorAvolio, Ennio
dc.contributor.authorBotti, Gerardo
dc.date.accessioned2020-09-15T18:21:33Z
dc.date.available2020-09-15T18:21:33Z
dc.date.issued2020-08-21
dc.identifier.urihttp://hdl.handle.net/10713/13706
dc.description.abstractThe spread of the novel human respiratory coronavirus (SARS-CoV-2) is a global public health emergency. There is no known successful treatment as of this time, and there is a need for medical options to mitigate this current epidemic. SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) receptor and is primarily trophic for the lower and upper respiratory tract. A number of current studies on COVID-19 have demonstrated the substantial increase in pro-inflammatory factors in the lungs during infection. The virus is also documented in the central nervous system and, particularly in the brainstem, which plays a key role in respiratory and cardiovascular function. Currently, there are few antiviral approaches, and several alternative drugs are under investigation. Two of these are Idelalisib and Ebastine, already proposed as preventive strategies in airways and allergic diseases. The interesting and evolving potential of phosphoinositide 3-kinase δ (PI3Kδ) inhibitors, together with Ebastine, lies in their ability to suppress the release of pro-inflammatory cytokines, such as IL-1β, IL-8, IL-6, and TNF-α, by T cells. This may represent an optional therapeutic choice for COVID-19 to reduce inflammatory reactions and mortality, enabling patients to recover faster. This concise communication aims to provide new potential therapeutic targets capable of mitigating and alleviating SARS-CoV-2 pandemic infection.en_US
dc.description.sponsorshipAgenzia Italiana del Farmaco, Ministero della Saluteen_US
dc.description.urihttps://doi.org/10.3389/fimmu.2020.02094en_US
dc.language.isoen_USen_US
dc.publisherFrontiers Media S.A.en_US
dc.relation.ispartofFrontiers in Immunology Open Accessen_US
dc.subjectCOVID-19en_US
dc.subjectinflammationen_US
dc.subjectPI3Ken_US
dc.subjectSARS-CoV-2en_US
dc.subjecttherapyen_US
dc.titlePI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19en_US
dc.typeArticleen_US
dc.identifier.doi10.3389/fimmu.2020.02094
dc.source.journaltitleFrontiers in Immunology
dc.source.volume11


This item appears in the following Collection(s)

Show simple item record